These results suggested the potential use of PD-1/PD-L1 inhibitors for the treatment of EGFR-mutant NSCLC and the potential benefits of adding EGFR TKI to PD(L)1. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.